Abstract 538P
Background
Thymic carcinoma (TC) is a rare, aggressive cancer without a standardized therapeutic approach in the metastatic context. Recently TCs have been shown to express PD-L1 and respond to single agent immunotherapy. However, small phase II studies have suggested that there may be an increase in severe adverse events. We investigated the role of chemoimmunotherapy (CIO) in a cohort of TC patients in the first line (1L) setting.
Methods
Patient data was retrospectively extracted from the Australian Registry and biObank of thoRAcic cancers (AURORA). Descriptive statistics was used for reports on efficacy and safety. Kaplan Meier analysis was used for overall survival (OS) estimates.
Results
Among 22 TC patients, 17 (77%) with metastatic disease from 3 hospitals were included in this analysis: 9 male, median age 67 years (Q1-Q3 52-72), median follow-up 23.6 months (11.8-39.0), squamous histology (SCC) 11 (65%). Among the 14 systemically treated patients (9 SCC), 8 received standard platinum based chemotherapy and 6 CIO with pembrolizumab in combination with a platinum backbone. Of these, 5 (83%) developed immune-related adverse events (irAE), incl. hypopituitarism, adrenal insufficiency, arthralgia, pneumonitis and skin toxicity. Pneumonitis was the only severe (≥G3) toxicity. No cardiac or neurological irAEs were reported. The objective response rate (ORR) was 50% in the chemo-only group and 67% in the CIO arm. In the CIO group 3 achieved a complete response (CR), 1 a partial response (PR), 1 stable disease (SD) and 1 progressive disease (PD). While 1 of the CR patients achieved remission with CIO alone, the other 2 received additional surgery or SBRT for oligoprogression and have remained in CR thereafter. The median number of pembrolizumab cycles was 17, 2 patients completed 2 years. The median duration of chemo-only response was 9.3 months (2.4 – 17.1) and of CIO response 8.1 months (2.5 – 14.8). Median OS in the chemo-only group was 32.3 months and not reached for the CIO group, with a median follow-up of 24.8 months (13.9-29.2).
Conclusions
CIO is a feasible first line treatment option in metastatic TC. Despite the high frequency of irAEs, only 1 patient had G3 or higher toxicity. With a high ORR and a subset of TC patients achieving durable responses, further studies using 1L CIO in TC are warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
S.E. Bowyer: Financial Interests, Personal, Advisory Board, Cabozantinib ad board: Ipsen; Financial Interests, Personal, Advisory Board, Selpercatinib ad board: Lilly; Financial Interests, Personal, Advisory Board, Cemiplimab ad board: Sanofi; Financial Interests, Personal, Advisory Board, pembrolizumab in H&N cancer Rx: MSD; Financial Interests, Personal, Advisory Board, Neoadjuvant Rx of lung cancer: Roche; Financial Interests, Personal, Invited Speaker, neoadjuvant lung cancer Rx: BMS; Financial Interests, Personal, Invited Speaker, Immunotherapy in lung cancer: MSD; Financial Interests, Personal, Invited Speaker, Cemiplimab in Rx of advanced cutaneous SCC: Sanofi; Non-Financial Interests, Personal, Principal Investigator: BMS, GSK, Genetech, Roche, Enliven Therapeutics Inc, FLX Bio, Lilly, Hummingbird Bioscience, WMBIO, Regeneron, Janssen, ALX Oncology, Replimmune. L. Warburton: Financial Interests, Personal, Advisory Board: Roche, Novartis, MSD, AstraZeneca, BMS. B. Solomon: Financial Interests, Institutional, Advisory Board: AstraZeneca, Novartis, Merck, Bristol Myers Squibb; Financial Interests, Personal, Invited Speaker: Pfizer, AstraZeneca, Roche/Genentech; Financial Interests, Personal, Advisory Board: Amgen, Roche-Genentech, Eli Lilly, Takeda, Janssen; Financial Interests, Personal, Full or part-time Employment, Employed as a consultant Medical Oncologist at Peter MacCallum Cancer Centre: Peter MacCallum Cancer Centre; Financial Interests, Personal, Member of Board of Directors: Cancer Council of Victoria, Thoracic Oncology Group of Australasia; Financial Interests, Personal, Royalties: UpToDate; Financial Interests, Institutional, Steering Committee Member, Principal Investigator and Steering committee Chair: Roche/Genentech, Pfizer; Financial Interests, Institutional, Steering Committee Member: Novartis. T. John: Financial Interests, Personal, Invited Speaker, Speaker tour Vietnam: AstraZeneca; Financial Interests, Personal, Invited Speaker, CTIO: Merck Sharp Dohme; Financial Interests, Personal, Advisory Board: BMS, AstraZeneca, Bayer, Specialised Therapeutics; Financial Interests, Institutional, Advisory Board: Roche, Novartis, Pfizer, Amgen, Takeda, PharmaMar; Financial Interests, Personal, Other, Speaker/Chair: ACE Oncology. All other authors have declared no conflicts of interest.
Resources from the same session
581P - The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer
Presenter: Wen-Chen Tang
Session: Poster Display
Resources:
Abstract
582P - Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
Presenter: Haiyang Chen
Session: Poster Display
Resources:
Abstract
583P - RHBDL2 promotes non-small cell lung cancer metastasis and osimertinib resistance by activating the RAS/MEK/ERK signaling pathway through interaction with FGFR
Presenter: jun Deng
Session: Poster Display
Resources:
Abstract
584P - Upfront aumolertinib for preventing symptomatic central nervous system(CNS) metastases in EGFR-mutant non-small cell lung cancer without baseline CNS metastasis
Presenter: Tangfeng Lv
Session: Poster Display
Resources:
Abstract
585P - Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Presenter: Tony S.K. Mok
Session: Poster Display
Resources:
Abstract
586P - Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
587P - Exploring the prevalence and characteristics of human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer: Analysis from a Malaysian cohort
Presenter: Ning Yi Yap
Session: Poster Display
Resources:
Abstract
588P - First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer
Presenter: Kaihua Lu
Session: Poster Display
Resources:
Abstract
590P - A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
Presenter: Ben Markman
Session: Poster Display
Resources:
Abstract
591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study
Presenter: Adam Pluzanski
Session: Poster Display
Resources:
Abstract